Hoffman-LaRoche has renewed enrolling patients in a clinical trial of a combination of Xeloda and Avastin as a therapy for colon cancer. Enrollment had been suspended early this year after the sudden deaths of four patients involved in the study. But researchers say their independent safety review board said mortality rates were similar across all groups. They added a cardiac monitoring plan to detect any other deaths in the study that might occur.
- here's the AP report [1]
Links:
[1] http://www.businessweek.com/ap/financialnews/D8HPHK4G0.htm?campaign_id=apn_home_down&chan=db